Free Trial
→ Trump’s national nightmare is here (From Porter & Company) (Ad)tc pixel

Emily Field Analyst Performance

Director, Head of European Pharmaceuticals Equity Research at Barclays

Emily Field is a stock analyst at Barclays in the medical sector, covering 3 publicly traded companies. Over the past year, Emily Field has issued 2 stock ratings, including hold and sell recommendations. While full access to Emily Field's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Emily Field's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Analyst Ranking
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
3 Last 3 Years
Buy Recommendations
0.00% 0 Buy Ratings
Companies Covered
3 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy0.0%0 ratings
Hold66.7%2 ratings
Sell33.3%1 ratings

Out of 3 total stock ratings issued by Emily Field at Barclays, the majority (66.7%) have been Hold recommendations, followed by 33.3% Sell.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NYSE
33.3% of companies on NYSE
1 company
NASDAQ
33.3% of companies on NASDAQ
1 company
OTCMKTS
33.3% of companies on OTCMKTS
1 company

Emily Field, an analyst at Barclays, currently covers 3 companies listed on NYSE, NASDAQ and OTCMKTS, with the majority traded on NYSE.

Coverage Focus

Sector IconSectorPercentage
Medical
3 companies		100.0%

Emily Field of Barclays specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
LARGE CAP PHARMA
1 company		33.3%
MED - BIOMED/GENE
1 company		33.3%
PHARMACEUTICAL PREPARATIONS
1 company		33.3%

Emily Field's Ratings History at Barclays

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
Export to Excel
CompanyReport DateActionReport Date Price12-Month
Price Target		Rating12-Month
Price & ROI		Details
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
7/30/2025Reiterated Rating$53.97Equal Weight
Galapagos NV stock logo
GLPG
Galapagos
1/23/2025Reiterated Rating$23.93Underweight
Today's Ratings
Top-Rated Stocks
More Ratings Tools